Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cryopreservation Improves Longer-Lasting Blood Supply

By LabMedica International staff writers
Posted on 01 Dec 2016
The development of highly efficient methods to cryopreserve cells, tissues, and organs is becoming exceedingly important to meet the increasing demands of emerging cellular therapies. More...
Cryopreservation of blood and stem cells has had tremendous impact on regenerative and transfusion medicine.

Currently, red blood cell (RBC) storage is limited to 42 days at 4 °C, which can result in blood shortages when high numbers of emergency transfusions are required. Although cryopreservation can extend the storage time to 10 years, major limitations to current protocols largely limit this preservation method to rare blood types and autologous RBCs.

Biochemists working with the Canadian Blood Services (Edmonton, AB, Canada) have examined a new class of small molecules with the potential to make the cryopreservation process more practical and give the cells and tissues a longer shelf life. Low-molecular-weight ice recrystallization inhibitors (IRIs) are ideal cryoprotectants that control the growth of ice and mitigate cell damage during freezing.

The team performed a detailed study correlating the ice recrystallization inhibition activity and the cryopreservation ability with the structure of O-aryl-glycosides. Many effective IRIs are efficient cryoadditives for the freezing of red blood cells (RBCs). One effective cryoadditive did not inhibit ice recrystallization but instead inhibited ice nucleation, demonstrating the significance of inhibiting both processes and illustrating the importance of this emerging class of cryoprotectants.

The team showed that two of the molecules in the class were effective at preventing ice from forming in red blood cells frozen at -80 °C. Adding the new protectants reduced the needed concentration of glycerol from 40% to between 10% and 15%. Lowering the amount of glycerol could help minimize the time required to prepare thawed red blood cells for transfusion, and thus, be ready for use in patients faster.

The authors concluded that the O-aryl-glycosides represent a novel class of small-molecule IRIs, many of which were effective cryoadditives used for the freezing of RBCs with reduced glycerol concentrations. The synthesis of these structurally simple molecules is amenable to large-scale preparation for use in cryopreservation applications to improve upon cryopreservation protocols of therapeutically important cells. The study was published on October 24, 2016, in the journal ACS Omega.

Related Links:
Canadian Blood Services


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.